Clinical Trials Logo
  1. Home
  2. Pulmonary Tuberculosis
  3. NCT06110533
  4. Details
NCT06110533 Clinical Trial

Epidemiological Study of Hospitalized Children for Pulmonary Tuberculosis at Strasbourg University Hospitals

Pulmonary Tuberculosis Clinical Trial

— TPE  

Official title:
Descriptive Epidemiological Study of Hospitalized Children for Pulmonary Tuberculosis at Strasbourg University Hospitals

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06110533
Other study ID # 8907
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 4, 2023
Est. completion date April 14, 2024

Study information
Verified date October 2023
Source University Hospital, Strasbourg, France
Contact Laurence WEISS, MD
Phone 33 3 88 12 83 95
Email laurence.weiss@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pulmonary tuberculosis is the most common form of tuberculosis in children; According to the WHO, tuberculosis pulmonary tuberculosis in children represents approximately 80% of all cases of tuberculosis in children. In 2020, there were approximately 1.0 million new cases of pulmonary tuberculosis among children worldwide. In France, childhood tuberculosis remains a rare disease; the most recent data show a rate of 3.3 cases per 100,000 inhabitants among children under 15 years old in 2019. Pulmonary tuberculosis in children can lead to complications such as bronchiectasis and pneumothorax. Children living in homes where an adult has a active tuberculosis, or children with diseases chronic, malnourished or suffering from HIV are more likely to contract tuberculosis. The aim of this research is to determine the incidence, identify the risk factors as well as the clinical forms of pulmonary tuberculosis in children hospitalized at Strasbourg University Hospitals between 2012 and 2022.

Recruitment information / eligibility
Status Recruiting
Enrollment 50
Est. completion date April 14, 2024
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria: - Child (1 to 17 years old) - Child hospitalized for pulmonary tuberculosis at Strasbourg University Hospital between January 1, 2012 and December 31, 2022. - Child and/or his/her parental authority who have not expressed their opposition to the reuse of data for scientific research purposes. Exclusion Criteria: - Subject and/or their parental authority having expressed their opposition to the re-use of the child's data for scientific research purposes.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) - CHU de Strasbourg - France Strasbourg

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence and risk factors for pulmonary tuberculosis in children hospitalized at Strasbourg University Hospital between 2012 and 2022 1 month after hospitalization for pulmonary tuberculosis
See also
  Status Clinical Trial Phase
Completed NCT02736864 - Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae N/A
Not yet recruiting NCT04055441 - A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
Completed NCT02349841 - Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis Phase 2
Completed NCT01927159 - Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers Phase 1
Active, not recruiting NCT01691534 - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) Phase 2
Completed NCT00803322 - Improving Community Based Tuberculosis Care in Ethiopia Phase 4
Completed NCT00834353 - Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis N/A
Withdrawn NCT03277742 - Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz N/A
Completed NCT00057434 - Vitamin A Therapy for Tuberculosis Phase 3
Not yet recruiting NCT06192160 - Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Phase 2
Recruiting NCT06127641 - Rehabilitation of People With Post-tuberculosis Lung Disease N/A
Recruiting NCT06058299 - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis Phase 2
Completed NCT04550832 - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) Phase 2
Completed NCT02912832 - Prospective Assessment of TBDx Feasibility N/A
Completed NCT01215851 - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) Phase 2
Recruiting NCT01503099 - Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease N/A
Completed NCT04608955 - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 Phase 2
Recruiting NCT05046366 - Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Completed NCT05896930 - Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis Phase 2
Completed NCT02279875 - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) Phase 2